Would you consider PARP inhibition in a patient with metastatic prostate cancer and a germline BRCA2 variant of unknown significance?

Or would you restrict such treatment to patients with known pathogenic germline BRCA mutations?

Answer from: Medical Oncologist at Academic Institution

Over 90% of BRCA2 variants of undetermined significance in the past have been reclassified as benign variants, and thus VUS's should be treated as non-pathogenic and should not lead to a change in therapy and would not be predicted to be PARP responsive. It would be reasonable to confirm the signifi...

Comments

Medical Oncologist at University of Minnesota–Masonic Cancer Center
Short answer: I completely agree with Dr. @Andrew ...

Please select the option that best describes you:

Would you consider PARP inhibition in a patient with metastatic prostate cancer and a germline BRCA2 variant of unknown significance?

Related Questions